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Abstract: Glutaredoxins are defined as thiol disulfide oxidoreductases that reduce 
disulfide bonds employing reduced glutathione as electron donor. They constitute a 
complex family of proteins with a diversity of enzymatic and functional properties. 
Thus, dithiol glutaredoxins are able to reduce disulfide bonds and deglutathionylate 
mixed disulfides between glutathione and cysteine protein residues. They could act 
regulating the redox state of sulfhydryl residues of specific proteins, while thioredoxins 
(another family of thiol disulfide oxidoreductases which employ NADPH as electron 
donor) would be the general sulfhydryl reductants. Some dithiol glutaredoxins such as 
human Grx2 form dimers bridged by one iron-sulfur cluster, which acts as a sensor of 
oxidative stress, therefore regulating the activity of the glutaredoxin. The ability to 
interact with iron-sulfur clusters as ligands is also characteristic of monothiol 
glutaredoxins with a CGFS-type active site. These do not display thiol oxidoreductase 
activity, but have roles in iron homeostasis. The three members of this subfamily in 
Saccharomyces cerevisiae participate in the synthesis of the iron-sulfur clusters in 
mitochondria (Grx5), or in signalling the iron status inside the cell for regulation of iron 
uptake and intracellular iron relocalization (Grx3 and Grx4). Such role in iron 
metabolism seems to be evolutionary conserved. Fungal cells also contain membrane-
associated glutaredoxins structurally and enzymatically similar to dithiol glutaredoxins, 
which may act as redox regulators at the early stages of the protein secretory machinery. 
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INTRODUCTION 
 
In the past, glutaredoxins (GRXs) have been defined as thiol oxidoreductases 
that employ glutathione in its reduced form (L-γ-glutamyl-L-cysteinyl-glycine, 
abbreviated as GSH) to regulate the redox state of protein disulfides or glutathione-
protein mixed disulfides (see reviews in [1-3]). In normal redox conditions, when the 
ratio between GSH and oxidized glutathione (GSSG) is high, GRXs can reduce the 
disulfide bonds with GSH as hydrogen donor. In these conditions, therefore, it is 
supposed that GRXs act as intermediates in the protein reduction process. However, in 
oxidant conditions, when the GSH/GSSG ratio decreases and the redox potential for the 
redox couple becomes less negative, GRXs can catalyze the glutathionylation of 
reduced sulfydryl groups in proteins [4]. Therefore,  GRXs can act as modulators of 
protein activity by regulating the glutathionylation state of sulfydryl groups in the 
protein molecules [5].  In addition to GRXs, the GRX system includes glutathione 
reductase (which reduces GSSG to GSH) and NADPH, which acts as hydrogen donor 
for glutathione reductase. The role of GRXs as protein reductants became evident for 
the first time when it was demonstrated that an Escherichia coli GRX was able to 
reduce ribonucleotide reductase (RNR) [1]. Later, it was shown that GRXs also can 
reduce other proteins, among them 3’-phosphoadenylylsulfate reductase, a key enzyme 
in the conversion of inorganic sulfate into sulfur amino acids. Thus, the regulatory role 
of GRXs on central metabolic processes seems clear. However, during the last decade it 
became evident that GRXs constitute an heterogeneous protein family whose members 
have a large structural and functional diversity [3,6,7]. Even more, some GRXs are not 
active in dehydroascorbate reduction or in deglutathionylation of low molecular 
substrates such as β-mercaptoethanol disulfide (HEDS) [8-11], which are two standard 
assays for measuring the thiol oxidoreductase activity of GRXs. 
Therefore, what defines a GRX? Structurally, all GRXs have a ‘thioredoxin-
fold’ structure (see below), which is formed by a four- or five-stranded β-sheet flanked 
by three or more α-helices on either side of the β-sheet [12]. However, the thioredoxin-
fold superfamily includes other members in addition to GRXs [13]. Besides, a large 
number of GRX molecules have a complex structure with different types of modules 
fused to the GRX module with the thioredoxin-fold structure [7]. On the other hand, 
GRXs have a common active site motif CxxC/S located at a surface loop that is 
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accessible to GSH. Other amino acid residues which are conserved in GRXs help to 
define a GSH groove that together with the active site residues, allows the interaction of 
a GSH molecule with a GRX monomer [3]. With these considerations, GRXs are 
defined on structural bases in addition to their ability to interact with GSH molecules. 
This leaves open the possibility for a large diversity of physiological functions and also 
for different molecular mechanisms of GRX action, as recent studies are revealing. In 
this review we will make emphasis on GRX studies in the yeast Saccharomyces 
cerevisiae, since this organism has allowed a diversity of experimental approaches 
(genetic, biochemical, cell and molecular biology) which have established the basis for 
further studies in multicellular organisms. 
 
GLUTAREDOXIN SUBFAMILIES 
 
 Depending on the number of cysteine residues at the active site, GRXs are 
currently classified into two subfamilies: dithiol (2-Cys) and monothiol (1-Cys) GRXs. 
In addition, land plants contain a third type of GRXs with a CCxx active site, and three 
additional GRXs classes with an active site motif different from the above ones have 
been defined in prokaryotic and eukaryotic organisms with photosynthetic metabolism 
[6,14]. These specific GRXs from photosynthetic organisms have been less well 
characterized, and will not be considered here. Although we will employ the above 
classification for dithiol and monothiol GRXs, it should be kept in mind that it does not 
necessarily reflect the phylogenetic relationships among GRXs [7], and some 1-Cys 
GRXs may display higher homology with 2-Cys molecules than with other 1-Cys 
molecules [15]. Most dithiol GRXs contain a CPYC active site, although in some of 
them the Pro residue may be substituted by Ser or the Tyr residue by Phe. S. cerevisiae 
has two dithiol GRXs, which share a sequence identity of 64%: Grx1 is located at the 
cytosol, while Grx2 has a large cytosolic pool and a minor pool at the mitochondrial 
matrix and outer membrane [16,17] (Fig. 1). The existence of two Grx2 pools results 
from alternative translation initiation from two in-frame AUG sites [17]. The shorter 
isoform remains at the cytosol, while the longer one is translocated to the mitochondrial 
matrix. This isoform can be processed by a mitochondrial peptidase resulting in a 
soluble matrix form, or left unprocessed as an outer mitochondrial membrane-associated 
form. Human cells also contain two GRXs at different cell compartments. Grx1 is 
cytosolic and participates in ribonucleotide and dehydroascorbate reduction, regulation 
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of transcription factors and apoptosis, while Grx2 has two isoforms (nuclear and 
mitochondrial) derived from the same gene by alternative transcription initiation and 
splicing [18,19]. Human Grx2 has the unusual active site motif CSYS, and the most N-
terminal Cys residue is coordinated to an Fe-S cluster with the structure [2Fe-2S]
2+
  
bridging two Grx2 monomers [20]. In addition to their thiol oxidoreductase activity, 
yeast Grx1 and Grx2 are also active as glutathione transferases (GSTs), that is, they are 
able to conjugate different small molecular weight organic compounds (generally of 
xenobiotic nature) to the sulfhydryl group of a GSH molecule [21]. These 
glutathionylated molecules are consequently degraded or transported into the vacuole, 
what constitutes a detoxification mechanism. 
 Monothiol GRXs were first described in S. cerevisiae, which contains three 
members of this subfamily: Grx3, Grx4 and Grx5 [22] (Fig. 1). They have homologues 
widely distributed among prokaryotic and eukaryotic organisms, and are characterized 
by the presence of a CGFS active site motif (reviewed in [23]). In eukaryotes, many of 
the monothiol GRXs contain more than one GRX module or domain in tandem, as well 
as domains of a different origin fused at the N-terminal region of the molecule. For 
instance, yeast Grx3 and Grx4 contain a thioredoxin-like domain fused to the GRX 
domain [24], while human PICOT protein is formed by a thioredoxin-like domain fused 
to two GRX domains in tandem [25]. The functional implications of such modular 
structure are unknown, but bioinformatics analyses have shown that fusion events have 
occurred repeatedly along evolution [7]. In S. cerevisiae, the thioredoxin-like domain of 
Grx3 is important for compartmentalization of the protein [24]. Different cell 
compartments contain monothiol GRXs in eukaryotic cells. Thus, S. cerevisiae Grx5 is 
located at the mitochondrial matrix [26], while Grx3 and Grx4 have been described at 
the nucleus [23] and also at the cytosol [27]. Location of human Grx5 has not been 
directly determined, although its functional characterization (see below) firmly supports 
a mitochondrial location as occurs with its yeast homologue. On the other hand, plant 
monothiol GRXs are present at the cytosol, chloroplasts and mitochondria, and probably 
also at the nucleus [6]. Members of this GRX subfamily display very low or null thiol 
disulfide oxidoreductase activity in standard enzyme assays for GRXs, although they 
may be able to deglutathionylate some glutathionylated protein substrates [8-11]. This 
deglutathyonulation ability occurs in prokaryotic and eukarytic monothiol GRXs. The 
reductant in the in vitro assays is GSH [8,9], or the couple ferredoxin plus ferredoxin-
thioredoxin reductase in the case of the green alga Chlamydomonas reinhardtii [10].   
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 Associating the concept of monothiol (1-Cys) GRX to the CGFS-type molecules 
should be revised due to the description of two additional GRXs in S. cerevisiae, Grx6 
and Grx7, respectively with the active site motifs CSYS and CPYS [15,28] (Fig. 1). 
Homologues of Grx6 and Grx7 are present in diverse fungal species, although not in 
other organisms, and both molecules have standard thiol disulfide oxidoreductase 
activity both in vitro and in vivo [15,29]. Purified Grx6 also displays GST activity, even 
higher than yeast Grx1 or Grx2 [30]. On the contrary, the oxidoreductase activity of 
Grx6 and Grx7 is considerably lower than the activity of the dithiol Grx1 and Grx2 
[15,29]. Sequence homology analyses result in grouping Grx6 and Grx7 close to dithiol 
GRXs [7]. Therefore, both primary structure and enzyme activity properties indicate 
that Grx6 and Grx7 are closer to dithiol GRXs than to CGFS-type GRXs. On the other 
hand, Grx6 and Grx7 are the first GRXs characterized as integral membrane proteins of 
the early secretory pathway, at Golgi in the case of Grx7 and endoplasmic reticulum 
(ER) and Golgi in the case of Grx6  [15,28]. S. cerevisiae Grx6 and Grx7 and their 
fungal homologues have a complex structure consisting of an N-terminal 
transmembrane domain, which is responsible for the insertion of the molecules at the 
membranes of the secretory vesicles, followed by a long linker domain and the GRX 
module (Fig. 1). The CS/PYS active site is positioned at the lumen of the vesicles [14].   
 Recently, another GRX has been described in S. cerevisiae, Grx8 [31] (Fig. 1). 
Its amino acid sequence supports a thioredoxin-fold structure for Grx8, which displays 
more sequence homology with dithiol GRXs than with other GRXs. The active site 
motif (CPDC) and the adjacent residues are more similar to thioredoxin-like proteins 
than to GRXs, although purified Grx8 has low but detectable thiol disulfide 
oxidoreductase activity in a standard GRX activity assay and can be reduced by GSH, 
which confirms its role as GRX [31]. Yeast mutants lacking Grx8 do not have an 
apparent phenotype, and therefore the physiological role of this atypical GRX remains 
unsolved.   
 
STRUCTURE OF GLUTAREDOXINS 
 
 Dithiol GRXs were the first GRXs characterized at biochemical and structural 
levels. Consequently, the three-dimensional structure of a number of dithiol GRXs has 
been determined experimentally and the corresponding data are available at RCBS 
Protein Data Bank (PDB). They are structurally defined by the thioredoxin-fold domain 
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and the conservation of a number of residues that constitute the GRX groove and/or are 
important for interactions with the GSH molecule [3]. The three-dimensional structure 
of S. cerevisiae Grx1 has been solved in detail [32] (PDB codes 3C1R and 3C1S 
respectively for the oxidized and glutathionylated forms). Compared to other dithiol 
GRXs for which the tertiary structure has been determined, yeast Grx1 has a number of 
conserved residues important for the GSH interactions (Fig. 2). These include Thr74, 
Val75 and Pro76, which interact with the glutamyl and cysteinyl groups of GSH, as 
well as Lys24, which is implicated in binding the glycine moiety of GSH [32]. The 
highly conserved Ile85, Gly86 and Gly87, located at the loop that connects β-sheet 4 
with α-helix 4, are important for the adequate orientation of this α-helix to allow 
forming the GSH groove. The CPYC active site is exposed to the exterior, in the loop 
between β-sheet 1 and α-helix 2. The crystal structures of oxidized and reduced S. 
cerevisiae Grx2 have also been solved very recently (PDB codes 3CTF and 3CTG 
respectively) [33]. Comparison of the three-dimensional structures of S. cerevisiae Grx1 
and Grx2 shows that both are very similar and that the residues involved in GSH 
binding are highly conserved. However, Asp89 in Grx1 is substituted by Ser123 in the 
equivalent position in Grx2, and it has been demonstrated that this change alone may 
explain the higher specific activity of Grx2 compared to Grx1 in enzyme assays with 
HEDS as substrate [33]. These two Asp and Ser residues are implicated in the 
interaction with the γ-glutamyl moiety of GSH [32,33]. 
 Some dithiol GRXs such as human Grx2 (CSYC active site) or poplar GrxC1 
(CGYC active site) incorporate a Fe-S cluster in the [2Fe-2S]
2+
 form that bridges two 
monomers to constitute an homodimeric GRX complex [20,34]. The Fe-S cluster is 
coordinated to each of the most N-terminal active site cysteines of the two GRX 
monomers and each of the cysteinyl residues of two GSH molecules. Therefore, GSH is 
directly involved in formation of the holo GRX dimer. Significantly, the absence of a 
proline residue in the active site of these two dithiol GRXs is a requisite for Fe-S 
binding [20,34]. In the case of human Grx2, the holodimer is enzymatically inactive, 
while the monomers are active. This has led to establish the hypothesis that the Fe-S 
cluster in the dimer would act as a redox sensor, and its disorganization upon oxidative 
stress would induce Grx2 activation [35,36].  
 In spite of their sequence similarity, the structural properties of S. cerevisiae 
Grx6 and Grx7 are different. Thus, recombinant Grx6 produced in E. coli is purified 
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mostly as a tetramer with two Fe-S clusters, while Grx7 is obtained as a dimer lacking 
Fe-S clusters [29]. In both cases, oligomerization is non-covalent. In Grx6, each Fe-S 
cluster is stabilized by GSH and bridges two monomers, as occurs with human Grx2 
and poplar GrxC1. The Grx6 N-terminal moiety is also necessary for stabilizing the 
tetramers. Remarkably, the active site of Grx6 (GSYS) is similar to that of human Grx2, 
except for the second cysteine residue. The crystal structure of the GRX domain of 
Grx6 has been determined [30] (Fig. 2). It reveals an extra β-sheet at the C-terminal 
region, which probably is also present in Grx7 based on sequence comparison. This 
additional structure localizes opposite to the GSH groove, and its functional role 
remains to be determined. Some of the amino acid residues which interact with the GSH 
molecule are equivalent to those important in S. cerevisiae Grx1 or Grx2 [30] (Fig. 2).  
 Diverse monothiol GRXs of the CGFS type have been purified in bacterial cells. 
In all cases they form non-covalent homodimers interacting with a [2Fe-2S]
2+
 cluster 
ligated to two GSH molecules [37-39]. The cysteine residue of the active site is required 
for Fe-S assembly, as well as some other residues conserved in such GRXs [37]. This 
situation is similar to that described for some dithiol GRXs (see above). However, 
crystallography analysis of the dimer structure of the Escherichia coli monothiol Grx4 
showed that besides the Fe-S cluster plus GSH ligand, other regions of the molecule are 
important for interaction between the two monomers [40]. This contrasts with dithiol 
human Grx2, where only the Fe-S cluster participates in monomer interactions [20]. 
Other important differences are observed when the monomeric [41] and dimeric [40] 
structures of E. coli Grx4 are compared. The monomer structure prevents the binding of 
the Fe-S cluster and the GSH molecule and, therefore, formation of the dimer. This 
together with the fact that the poplar monothiol GrxS14 can deliver Fe-S clusters in 
vitro  to apoproteins [39], may suggest that monothiol GRXs in their dimeric form 
would act as Fe-S reservoirs or scaffolds to deliver them to receptor proteins (discussed 
below). Structural analyses of other monothiol GRXs such as S. cerevisiae Grx5 are 
under way [42], and the three-dimensional structure of Grx5 has been deposited in PDB 
(code 3GX8) (Fig. 2). 
 
CELLULAR FUNCTIONS OF DITHIOL GLUTAREDOXINS    
 
Studies in bacterial and mammalian cells (reviewed in [2,3]) demonstrated that 
dithiol GRXs act as reductants of sulfhydryl groups in enzymes which alternate the 
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redox state of cysteine residues essential for their catalytic cycle, such as RNR 
(involved in conversion of ribonucleotides to deoxynucleotides) or 3’-
phosphoadenylylsulfate reductase (participating in the assimilation of sulfate to reduced 
sulfur compounds such as cysteine or methionine). In those processes, GRXs act in 
parallel to the thioredoxin (TRX) system, which is composed by TRXs, TRX reductase 
and NADPH, which acts as direct electron donor [1]. The relative contribution of both 
dithiol GRXs and TRXs seems to vary between organisms. Thus, in E. coli Grx1 
appears to be the main in vivo contributor for RNR reduction [43]. On the contrary, in S. 
cerevisiae only the double trx1 trx2 mutant accumulates an oxydized form of RNR, 
while the grx1 grx2 mutant is not affected [44]. Therefore, in this yeast TRXs seem to 
be the main enzymes responsible for RNR reduction. This is in accordance with another 
study demonstrating that TRXs are required in S. cerevisiae for maintaining the 
deoxyribonucleotide pools during the S phase [45].   
As mentioned above, dithiol GRXs are also deglutathionylating enzymes, that is, 
they are able to efficiently reduce mixed disulfides formed between GSH and protein 
sulfydryl groups in in vitro assays. Protein glutathionylation can be envisaged as a 
mechanism both to protect proteins from irreversible oxidation of sulfhydryl groups and 
to regulate protein functions [5,46,47]. For instance, human Grx1 regulates in vivo 
glutathionylation of specific proteins such as Ras, inhibitory kappa B kinase, actin or 
caspase 3 [48-51]. However, knockout mice that do not express Grx1 are not especially 
sensitive to oxidants [52], what argues against a general protective role upon oxidative 
stress. A recent study [52] has shown that a S. cerevisiae mutant lacking both Grx1 and 
Grx2 does not display protein hyperglutathionylation. On the contrary, a mutant lacking 
the cytosolic TRXs Trx1 and Trx2 has constitutively high levels of protein  
glutathionylation. Therefore, at least in S. cerevisiae, it is the TRX system which seems 
to regulate the general glutathionylation state of cell proteins [53]. Such 
glutathionylation levels become increased at stationary phase [53].  
Which is then the physiological role of dithiol GRXs? In the case of human 
Grx2, this might act as a sensor of oxidative stress through its ligated Fe-S cluster 
[20,35]. Deorganization of the cluster by oxidants would release the individual 
monomers in their active form. Still, the specific in vivo protein targets of human Grx2 
are not known. However, most dithiol GRXs do not seem to be ligated to Fe-S clusters 
and therefore, the oxidative sensor role would be specific for a subset of them. In S. 
cerevisiae overexpression of Grx1 enhances protection against superoxide anion and 
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hydroperoxides, while overexpression of Grx2 allows resistance to hydroperoxides [16], 
which suggests that both GRXs are partially specialized. Grx1 and Grx2 seem to act 
cooperatively with two GSTs (Gtt1 and Gtt2) in protection against hydroperoxides and 
toxic xenobiotics, based on studies with multiple mutants [21]. In addition, Grx1 and 
Grx2 detoxify the herbicide 2,4-dichlorophenoxyacetic acid [54], which generates 
hydroxyl radicals. Also, recent studies have shown that Grx1 and Grx2 have 
overlapping roles in S. cerevisiae in protection against toxicity by selenite [55,56], 
which is also a generator of reactive oxygen species (ROS). Therefore, yeast Grx1 and 
Grx2 might target specific proteins either with an important function in protection 
against oxidants or which would be highly sensitive to such oxidants. Such targets 
remain to be characterized. Two recent studies may shed some light on the 
physiological role of the mitochondrial fraction of yeast Grx2. While a mutant lacking 
the cytosolic isoform of Grx2 does not display a different phenotype with respect to 
wild type cells, the mitochondrial isoform of Grx2 confers more tolerance to oxidative 
stress caused by high concentrations of hydrogen peroxide [57]. Related to this, in in 
vitro assays yeast Grx2 is specifically able to deglutathionylate the S. cerevisiae 1-Cys 
peroxiredoxin, what is an essential step to regenerate active peroxiredoxin [58]. Given 
the role of peroxiredoxins in peroxide detoxification, this could explain the protective 
role of mitochondrial Grx2 against oxidative stress generated by peroxides. It is 
remarkable that in the case of the mitochondrial 1-Cys peroxiredoxin, Grx2 substitutes 
the general role of TRXs as peroxiredoxin reductants.   
Another aspect that awaits full characterization is the functional overlapping 
between the TRX and GRX systems. At a biochemical level, such overlapping is 
demonstrated by the fact that S. cerevisiae cells devoided of GSH reductase still are able 
to reduce oxidized glutathione through TRX reductase, and therefore that the TRX 
system can function as an alternative to maintain the GSH pool in vivo [59]. A similar 
situation may occur in Arabidopsis [60]. This alternative role of TRX reductase might 
explain why a quadruple trx1 trx2 grx1 grx2 mutant is not viable in S. cerevisiae [61]. 
 
MONOTHIOL GLUTAREDOXINS AND IRON HOMEOSTASIS 
 
 During the last decade our knowledge on the function of monothiol GRXs of the 
CGFS type has increased significantly, revealing their relationship with iron metabolism 
and homeostasis inside the cell [23,62]. Initial studies were mostly made in S. cerevisiae 
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combining genetic and biochemical approaches, and were then extended to other 
organisms including plants and animals. Thus,  S. cerevisiae Grx5 was first 
characterized as a GRX localized at the mitochondrial matrix, which participates in the 
synthesis of Fe-S clusters through the ISC pathway [26]. This is one of the several 
pathways employed for the synthesis of these clusters in living cells. In eukaryotes it is 
the mechanism through which the clusters are assembled at mitochondria using an 
Isu1/Isu2 scaffold (S. cerevisiae terminology). From the Isu1/Isu2 complex the Fe-S 
clusters are then transferred to mitochondrial apoproteins or exported across the 
mitochondrial envelope to be assembled into extramitochondrial proteins through the so 
called CIA machinery [63]. This export requires a number of mitochondrial envelope 
proteins as well as GSH. Other studies mapped the Grx5 function in the transfer of the 
assembled Fe-S clusters from the Isu1/Isu2 complex to the apoproteins, in combination 
with a Hsp70-type Ssq1 chaperone [64]. The lack of Grx5 leads to iron accumulation 
inside the cells, unability for respiratory growth and deffects in the activity of enzymes 
requiring Fe-S clusters as cofactors [26]. These phenotypes are similar to those of other 
ISC mutants. Using the yeast grx5 mutant model, it has been shown that bacterial, 
parasite, plant and vertebrate homologues are able to substitute for the function of yeast 
Grx5 [11,39,65,66], pointing to a functional conservation during evolution. The 
deficiency of Grx5 in zebrafish embryos causes hypocrhromic anemia in shiraz 
mutants, which can be explained because the inability to assemble Fe-S clusters, 
consequent activation of cytosolic Iron Regulatory Protein 1 (IRP1) and inhibition of 
the sysnthesis of the first enzyme of the heme synthesis pathway [67]. This phenotype 
was reproduced in wild-type embryos injected with grx5 antisense RNA, and expression 
of Grx5 from other organisms including S. cerevisiae could rescue the shiraz phenotype 
[67]. These studies therefore revealed for the first time the relationship between the 
Grx5 function, the synthesis of Fe-S clusters and iron metabolism. A later study 
reported that a mutation in an intron of the GRX5 gene in a human patient resulted in a 
large decrease of GRX5 expression, deficiency in heme synthesis and sideroblastic 
anemia [68]. Finally, a recent work [69] has shown that Fe-S clusters can be 
reconstituted in vitro in recombinant human Grx5, that siRNA-mediated depletion of 
Grx5 in human cells inhibits maturation of Fe-S proteins and that such deficiency in 
erythroid cells results in accumulation of mitochondrial iron, depletion of cytosolic iron 
and impairment of heme synthsis, as a consequence of altered activity of IRP1. These 
alterations can explain the sideroblastic anemia-associated phenotype resulting from 
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decreased expression of human GRX5 mRNA [68,69]. Grx5 deficiency has also been 
related to increased protein oxidative damage in yeast cells [22,26], maybe because the 
abnormal iron accumulation inside the cell as a result of the disturbance of Fe-S cluster 
synthesis and signalling of the intracellular iron state (see below). Consequent with this, 
inhibition of Grx5 synthesis in human osteoblasts causes increased ROS formation and 
apoptosis [70].  
 The detailed role of Grx5 in the synthesis of the Fe-S clusters is not known. 
Based on the in vitro deglutathionylation activity of monothiol GRXs, it can be 
hypothesized that Grx5 could act maintaining in a reduced form the sulfydryl groups of 
acceptor proteins of Fe-S clusters at mitochondria, or alternatively it could regulate the 
redox state of components of the ISC machinery acting at late steps of the cluster 
assembly pathway. However, recently it has been shown that poplar GrxS14, a 
chloroplast homologue of Grx5, binds directly Fe-S clusters through the CGFS active 
site and is able to transfer in vitro these clusters to apoproteins such as ferredoxin [39]. 
This opens the possibility that Grx5 proteins in fact are intermediates in the transfer of 
Fe-S clusters from the scaffold complex Isu1-Isu2 (or its homologues) to the target 
proteins, a role that still has to be confirmed in vivo. If this were the case, then the 
physiologically relevant role of Grx5 in mitochondria would not be due to its activity as 
thiol disulfide oxidoreductase but to its ability to form complexes with Fe-S clusters and 
GSH molecules. As above mentioned, structural studies indicate that the three-
dimensional  structure of these monothiol GRXs is different in their monomeric and Fe-
S and GSH-ligated dimeric form [40], a fact that would support the unidirectionality of 
the Fe-S transfer from Grx5 to the apoprotein. 
 Other S. cerevisiae CGFS-type monothiol GRXs, Grx3 and Grx4, have a nuclear 
and/or cytoplasmic location [23,27]. Two separate studies [71,72] demonstrated that 
they regulate the activity of the Aft1 transcription factor. Upon iron limitation, Aft1 
activates the expression of genes involved in (i) iron assimilation through the high-
affinity pathway and the siderophore-mediated pathway, and (ii) vacuolar iron transport 
[73,74]. Altogether, they are known as the iron regulon. Upon iron depletion, Aft1 
localizes in the nucleus and upregulates the genes of the regulon, while in iron-replete 
conditions it moves to the cytosol and the iron regulon is not expressed  [75,76]. 
Inhibition of mitochondrial Fe-S cluster synthesis also causes activation of the iron 
regulon [77-79], and it has been proposed that a mitochondrial Fe-S protein (or another 
type of molecule) could act as a sensor of the intracellular iron status transferring the 
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corresponding signal to Aft1 [80]. Grx3 and Grx4 form a complex with Aft1, and in the 
absence of the two GRXs Aft1 remains constitutively localized in the nucleus [71,72]. 
In a grx3 grx4 mutant, the consequent upregulation of the Aft1 regulon independently 
of the intracellular iron status results in higher than normal intracellular iron levels and 
hypersensitivity to oxidative stress [71,72]. Recently, it has been demonstrated that 
Grx3 and Grx4 are Fe-S proteins in vivo (in addition to the previous demonstration in 
vitro [37]), and that such ligated clusters are essential for the signalling role on Aft1 
activity [81]. Thus, mitochondrial synthesis of Fe-S clusters would be essential for such 
signalling events. Fig. 3 summarizes the role of the three monothiol GRXs in the 
expression of the iron regulon in S. cerevisiae. 
 The Aft1/Grx3-4 complex contains two additional proteins, Fra1 (an 
aminopeptidase P-like protein) and Fra2 (a BolA homologue) [27]. In the absence of 
any of these two proteins there is also constitutive upregulation of the iron regulon. In 
vitro reconstitution experiments have demonstrated that Fra2 helps stabilizing the 
Aft1/Grx3-4 complex [82]. Comparative genomic analyses demonstrate that an strong 
cooccurrence exists in organisms between BolA-like proteins and CGFS-type GRXs 
[6,83]. This together with the studies demonstrating physical interactions between 
members of the two families suggest that the functional relationships between Fra and 
Grx3/4 homologues are evolutionary conserved.   
 The role of Aft1-like proteins in regulating iron homeostasis is circumscribed to 
some fungal species. However, the participation of homologues of Grx3 and Grx4 in the 
control of intracellular iron levels seems to be a more general trait. Thus, in the fission 
yeast Schizosaccharomyces pombe iron homeostasis is transcriptionally controlled by 
two factors, Fep1 (which represses expression of genes for iron acquisition) and Php4 
(which represses genes for iron-requiring proteins) [84]. There is a cross-talk between 
both factors, since expression of the php4
+
 gene is repressed by Fep1. Upon iron 
repletion, S. pombe Grx4 inactivates the repressor function of Php4, which is then 
exported to the cytosol, therefore allowing expression of iron-requiring proteins [85]. 
Therefore, CGFS-type GRXs seem to exert a rather general role in the regulation of 
transcriptional factors controlling intracellular iron homeostasis, probably acting as iron 
sensors. The exact mechanism through which Grx3/4 proteins transduce the signals of 
the iron status remain to be elucidated, but it is tempting to relate it to their properties as 
Fe-S proteins.  
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 In fact, Grx3 and Grx4 have additional functions in S. cerevisiae. In some 
genetic backgrounds a double mutant lacking both proteins is not viable [81,86], which 
can not be explained based exclussively on the Aft1-mediated effects on the iron 
regulon. Grx4 interacts and is phosphorylated by Bud32, a protein kinase member of the 
EKC/KEOPS complex, otherwise involved in transcription control and telomere 
homeostasis [86,87]. Upon Grx3 and Grx4 depletion all iron-requiring reactions in the 
cytosol, mitochondria and nucleus are impaired, including the synthesis of heme, di-iron 
centers and Fe-S clusters [81]. Thus, Grx3 and Grx4 would be central regulators of 
intracellular iron trafficking in yeast cells through their Fe-S bound cluster. 
 The PICOT protein (also named GLRX3 or Grx3) is the homologue of Grx3 and 
Grx4 in human cells, and until the moment it has not been related to iron metabolism 
but to other regulatory processes. It was first characterized as a protein kinase C theta 
(PKC-θ)-binding protein in human T lymphocytes. In these cells, it inhibits PKC-θ-
dependent activation of JNK protein kinase and the AP-1 and NF-κB transcription 
factors [25]. On the other hand, PICOT is activated during cardiac hypertrophy, 
regulating cardiomyocyte contractility [88]. In cardiomyocytes, PICOT binds to muscle 
LIM protein in competition with calcineurin [89]. In this way, it disrupts calcineurin-
mediated activation of the NFAT factor, which itself is a regulator of cardiomyocyte 
contractility [89]. Nevertheless, a mouse null mutant in the PICOT gene is unable to 
complete embryonic development [90], indicating that PICOT may have other essential 
roles in addition to PKC-θ and muscle LIM protein binding in mammalian cells. All 
there activities depend on the cysteine residue of the GRX domain of the molecule. 
Structural studies with purified recombinant PICOT have shown that this is also an 
homodimeric Fe-S protein in which each of the two GRX domains of each monomer is 
ligated to a Fe-S cluster that acts as a bridge with the other monomer [91]. The two 
clusters of the homodimer could act as regulators of the protein ability to interact with 
its targets.   
 
GLUTAREDOXINS AND THE PROTEIN SECRETORY PATHWAY 
 
Membranous compartments of the secretory machinery, and in particular the ER, 
constitute a cellular environment where ROS are generated [92,93]. This is the 
consequence of protein sulfhydryl oxidation and subsequent formation of disulfide 
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bridges required for correct protein folding. At least two activities are required for this 
process: a member of the protein disulfide isomerase (PDI) family, and a FAD-
dependent oxidase. Both  form an electron transport chain that transfers electrons from 
the protein cysteine groups to oxygen, although ROS are also formed accidentally. As a 
consequence, the early secretory pathway compartment constitutes a highly oxidative 
environment. In S. cerevisiae, Pdi1 and Ero1 are respectively the isomerase and the 
oxidase of the ER transport chain for protein protein folding, being both essential for 
yeast cell growth [91]. The physiological function of Ero1 has been partially elucidated 
by employing conditional mutants or mutants with reduced activity [94,95]. Thus, ero1-
1 is a thermosensitive mutant that at the restrictive temperature is unable to fold 
properly secretory proteins such as carboxypeptidase Y, and whose defects are partially 
suppressed by oxidants of sulfhydryl groups such as diamide and enhanced by 
reductants such an dithiothretiol. In addition, GSH is required at the ER for correct 
functioning of the secretory machinery [96]. These observations have led to propose a 
relationship between redox control and protein secretion [92].  
 Most secretory proteins are cotranslationally folded while transferred to the ER. 
However, a subgroup of proteins with a transmembrane domain at the polypeptide C-
terminus (named tail-anchored proteins) are inserted post-translationally at diverse 
membranous organelles, among them the ER and the Golgi apparatus [97]. 
Compartmentalization of such proteins at the early secretory pathway has been 
characterized recently in S. cerevisiae, and it involves a GET machinery formed by a 
recruiting Get3 protein and a Get1/Get2 complex that inserts the tail-anchored proteins 
at the ER/Golgi membranes  [98,99]. The GET complex is dependent on the cellular 
redox state, since formation of Get3 dimers (required for the activity of the protein) 
requires that two C-terminal cysteine residues are reduced [100]. This again establish a 
relationship between compartimentalization of a subset of proteins at the early secretory 
pathway and redox regulation of sulfhydryl groups.  
 In fungal cells, Grx6 and Grx7 could be such redox regulators at RE/Golgi, 
based on their location as integral membrane components at those compartments, 
although few data exist at the moment to sustain that hypothesis. Phenotypic analyses of 
grx6 and grx7 mutants indicate that the double mutant has increased tolerance to 
tunycamicin, an inhibitor of N-glycosylation of secretory proteins [15], and that in some 
genetic backgrounds the grx6 mutant is hypersensitive to oxidants [28]. However, such 
mutants have not induced the unfolded protein response [28], a signaling cascade 
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through which eukaryotic cells activate expression of diverse chaperones and heat shock 
proteins among others, in response to insults causing protein unfolding in the ER 
[101,102]. This indicates that Grx6 and Grx7 may play non-general but specific roles in 
redox regulation of protein secretion. 
 
CONCLUDING REMARKS   
 
Dithiol and monothiol GRXs seem to have rather different functions. Members of the 
first subfamily, acting as disulfide reductants, may be redox regulators of specific target 
proteins. Some of these dithiol GRXs, by having a slightly modified active site, have 
acquired the ability to bind Fe-S clusters, which could act as sensors of oxidant 
conditions. While Fe-S cluster ligation is the exception among dithiol GRXs, in the case 
of monothiol GRXs the ability to interact with Fe-S clusters seems to be general, and 
these GRXs may act as intermediates in the transfer of the clusters to receptor proteins. 
This activity seems to be important for the physiological role of monothiol GRXs in 
processes related to iron metabolism. 
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FIGURE LEGENDS 
 
Fig. (1). Domain structure of S. cerevisiae GRXs. 
The position of the most N-terminal cysteine of the active site is indicated in each case, 
as well as the cleavage site of the mitochondrial targeting sequence (MTS) and the 
residues limiting the transmembrane (TM) domain.  
 
Fig. (2). Three-dimensional structures of S. cerevisiae GRXs. 
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The structures of glutathionylated Grx1 (PDB code 3C1S), monomeric Grx6 (3L4N) 
and monomeric Grx5 (3GX8) are represented using Swiss-PdbViewer 4.0.1. The active 
site cysteine residues, as well as other residues important for interaction with GSH, are 
indicated. Secondary structure domains are also labelled. See Ref. 32 and 30 for more 
details on the structures of Grx1 and Grx6 respectively. Note that only the structure of 
the GRX domain of Grx6 was determined. The residues important in Grx5 for 
interaction with GSH have been extrapolated from data on E. coli Grx4 in Ref. 40. 
 
Fig. (3). Role of monothiol GRXs in the expression of the iron regulon in S. 
cerevisiae. 
Under iron replete conditions the mitochondrial ISC machinery, including Grx5, is 
functional for the synthesis of  Fe-S clusters (here depicted by blue and yellow circles). 
An uncharacterized intermediate containing an Fe-S cluster acts as a signal that is 
transmitted to the cytosol. Grx3/4 with its Fe/S cluster ligand forms a complex with 
Fra1/2 and with Aft1, which is retained at the cytosol. In these conditions, the iron 
regulon is not expressed. Under iron deprivation, the ISC machinery does not function 
optimally and the Fe-S mitochondrial signal is not exported to the cytosol. Grx3/4 still 
forms a complex with Fra1/2 but not with Aft1, which is internalized into the nucleus, 
allowing expression of the iron regulon.  
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